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How can Plant Genetic Engineering Contribute to Cost-Effective Fish Vaccine
Development for Promoting Sustainable Aquaculture?
Abstract
Aquaculture, the fastest growing food-producing sector, now accounts for nearly 50 % of the world’s food
fish (FAO in The state of world fisheries and aquaculture. FAO, Rome, 2010). The global aquaculture
production of food fish reached 62.7 million tonnes in 2011 and is continuously increasing with an
estimated production of food fish of 66.5 million tonnes in 2012 (a 9.4 % increase in 1 year, FAO,
www.fao.org/fishery/topic/16140). Aquaculture is not only important for sustainable protein-based food
fish production but also for the aquaculture industry and economy worldwide. Disease prevention is the
key issue to maintain a sustainable development of aquaculture. Widespread use of antibiotics in
aquaculture has led to the development of antibiotic-resistant bacteria and the accumulation of
antibiotics in the environment, resulting in water and soil pollution. Thus, vaccination is the most effective
and environmentally-friendly approach to combat diseases in aquaculture to manage fish health.
Furthermore, when compared to >760 vaccines against human diseases, there are only about 30 fish
vaccines commercially available, suggesting the urgent need for development and cost-effective
production of fish vaccines for managing fish health, especially in the fast growing fish farming in Asia
where profit is minimal and therefore given high priority. Plant genetic engineering has made significant
contributions to production of biotech crops for food, feed, valuable recombinant proteins etc. in the past
three decades. The use of plants for vaccine production offers several advantages such as low cost,
safety and easy scaling up. To date a large number of plant-derived vaccines, antibodies and therapeutic
proteins have been produced for human health, of which a few have been made commercially available.
However, the development of animal vaccines in plants, especially fish vaccines by genetic engineering,
has not yet been addressed. Therefore, there is a need to exploit plant biotechnology for cost effective
fish vaccine development in plants, in particular, edible crops for oral fish vaccines. This review provides
insight into (1) the current status of fish vaccine and vaccination in aquaculture, (2) plant biotechnology
and edible crops for fish vaccines for oral administration, (3) regulatory constraints and (4) conclusions
and future perspectives.
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Abstract Aquaculture, the fastest growing food-producing sector, now accounts for nearly 50 % of the world’s
food fish (FAO in The state of world fisheries and aquaculture. FAO, Rome, 2010). The global aquaculture production of food fish reached 62.7 million tonnes in 2011
and is continuously increasing with an estimated production of food fish of 66.5 million tonnes in 2012 (a 9.4 %
increase in 1 year, FAO, www.fao.org/fishery/topic/16140).
Aquaculture is not only important for sustainable proteinbased food fish production but also for the aquaculture
industry and economy worldwide. Disease prevention is
the key issue to maintain a sustainable development of
aquaculture. Widespread use of antibiotics in aquaculture
has led to the development of antibiotic-resistant bacteria
and the accumulation of antibiotics in the environment,
resulting in water and soil pollution. Thus, vaccination is
the most effective and environmentally-friendly approach
to combat diseases in aquaculture to manage fish health.
Furthermore, when compared to [760 vaccines against
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human diseases, there are only about 30 fish vaccines
commercially available, suggesting the urgent need for
development and cost-effective production of fish vaccines
for managing fish health, especially in the fast growing fish
farming in Asia where profit is minimal and therefore given
high priority. Plant genetic engineering has made significant contributions to production of biotech crops for food,
feed, valuable recombinant proteins etc. in the past three
decades. The use of plants for vaccine production offers
several advantages such as low cost, safety and easy scaling up. To date a large number of plant-derived vaccines,
antibodies and therapeutic proteins have been produced for
human health, of which a few have been made commercially available. However, the development of animal
vaccines in plants, especially fish vaccines by genetic
engineering, has not yet been addressed. Therefore, there is
a need to exploit plant biotechnology for cost effective fish
vaccine development in plants, in particular, edible crops
for oral fish vaccines. This review provides insight into (1)
the current status of fish vaccine and vaccination in aquaculture, (2) plant biotechnology and edible crops for fish
vaccines for oral administration, (3) regulatory constraints
and (4) conclusions and future perspectives.
Keywords Aquaculture  Food security  Fish vaccine 
Plant genetic engineering  Regulatory constraints

Introduction
Fish is an excellent animal protein source and contains a
wide range of essential human nutrients. Up to 80 % of the
world’s fish production is used for human consumption,
indicating the important role of aquaculture for food
security. Fisheries and aquaculture play also an important
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role in the livelihoods of millions of people worldwide
from the small-scale inland fishermen who harvest fishes
from lakes and rivers to the industrial scale fish farming.
Thus, sustainable fish farming contributes considerably to
food security (www.fao.org).
Aquaculture is the farming of aquatic organisms
including fish, crustaceans, molluscs and aquatic plants.
Fisheries and aquaculture make important contributions to
the human population as protein sources. The global
aquaculture production of food fish reached 62.7 million
tonnes in 2011 and is continuously increasing with an
estimated production of food fish of 66.5 million tonnes in
2012 (a 9.4 % increase in 1 year, FAO, www.fao.org/
fishery/topic/16140). In the past five decades, the world fish
supply has rapidly increased with an average growth rate of
3.2 % per year and constitutes an important source of
nutrition and animal protein for humans (FAO 2012;
http://www.fao.org, Fig. 1). This is particularly the case in
Asia, where approximately 90 % of the total global aquaculture products comes from. Among the Asian countries,
China alone produces ca. 70 % of the world total volume
of aquaculture products and has become the largest producer of farmed seafood in the world, with an increase of
490 % since 1978 (Ellis 2009). It is estimated that in the
next decade total production from both capture and aquaculture will exceed that of beef, pork or poultry. Due to
higher demand for fish, world fisheries and aquaculture
production are projected to reach about 172 million tonnes
in 2021, of which aquaculture is projected to reach about
79 million tonnes, rising by 33 % over the period
2012–2021 (FAO 2012, http://www.fao.org). This boom in
aquaculture will help to achieve certain millennium
development goals either directly (e.g. eradication of
extreme poverty and hunger) or indirectly (e.g. substantial
improvement in economies). However, aquaculture is as
vulnerable to adverse impacts of disease and unfavourable
environmental conditions as is farming of other animals.
Disease outbreaks in recent years have affected Atlantic
salmon, oyster and marine shrimp farming in several
countries of the world, resulting in partial or sometimes
total loss of production. In 2010, aquaculture in China
suffered production losses of 1.7 million tonnes caused by
natural disasters, diseases and pollution. Disease outbreaks
virtually wiped out marine shrimp farming production in
Mozambique in 2011 (FAO 2012). Fish diseases not only
pose a threat to the aquaculture industry but also to human
livelihood and health. Apart from zoonoses, use of certain
chemicals and antibiotics for fish health also pose certain
risks to the environment, human health and food security
(for a review see Sapkota et al. 2008). Management of
aquatic animal health is therefore an important issue for
food security, to protect livelihoods of millions of people,
the aquaculture industry and the environment.
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Fig. 1 Worldwide fish production in five decades. Data source
(www.fao.org/fishery/aquaculture)

History and current status of fish vaccines
and vaccination approaches
Compared with human vaccine history starting from the
discovery of vaccination by Edward Jenner in 1796 leading
to production of [760 vaccines for protecting human
health, fish vaccine development has a very short history
with roughly 40 years since the 1970s. It took over three
decades from the first scientific report describing fish
vaccination using an inactivated orally administrated Aeromonas salmonicida vaccine. The first licensed fish vaccine was made commercially available in 1976 (Evelyn
1997). The first fish vaccine was produced from killed
Yersinia ruckeri, and used to protect fishes against enteric
redmouth (ERM) by oral administration. Soon after the
release of ERM oral fish vaccine, a new vaccine for Vibrio
anguillarum became available in the USA with vaccination
via immersion. These were followed with the release of
Furunculosis vaccines in Europe in the 1980s. To date,
there are no more than 30 commercial vaccines for the
prevention of a wide range of fish diseases, with a few
more under development (Smith 2008). The economic,
environmental and animal welfare benefits have been
recognised as a result of the widespread use of vaccines in
the aquaculture industry. The potential from vaccines for
lower mortality, improved growth efficiency and higher
yields is now a critical factor in disease management programmes in aquaculture. To date, commercially used fish
vaccines are mainly: killed vaccines such as inactivated
virus or bacterial antigens, subunit vaccines and recombinant vaccines with humoral (antibody) responses, or live,
attenuated and DNA vaccines for cytotoxic T cell response
(Plant and LaPatra 2011, http://www.pharmaq.no).
At present, three main delivery approaches are used for
fish vaccination: (1) injection vaccination, (2) oral vaccination, and (3) immersion vaccination (including bath and
spray vaccination). The advantages and drawbacks of each
vaccination method are summarized in Table 1.

Plant Mol Biol (2013) 83:33–40
Table 1 Fish vaccination
methods and their advantages
and drawbacks [adapted from
Plant and LaPatra (2011) and
http://www.pharmaq.no]
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Vaccination
method

Advantages

Drawbacks

Injection

Most common method of vaccine delivery
in fish

Not feasible for fishes under 20 g

Intraperitoneal
(adjuvanted or
not)
Intramuscular
(DNA)

Effective in generating both humoral
(antibody) and cellular cytotoxic
response

Stressful for the fish due to handling and
anesthetizing
Labour intensive

Protection is of long duration

Expensive (high labour costs or
expensive injection machine)

Ideal delivery method via feed

Large amount of antigen needed

Microencapsulation

Easiest, no technical skill required

Poor and short-term protection (except
for Y. ruckeri and V. anguillarum).

Bio-encapsulation

Protection from the digestive system

Oral

No handling stress for the fish
No additional labour cost

Gastric degradation can affect
protective antigen

No investment on instrument required
Feasible for mass vaccination of all sizes
of fishes
Simple and suitable for mass vaccination

Not suitable for all farmed fishes

Bath

Less stress for the fish than injection

Spray
Dip

Lower labour costs
Less risk to vaccination team

Stressful for the fish because of netting
and transportation prior to spray
vaccination

Immersion by

Large amount of vaccine required in the
case of the bath method
Lower level of protection and duration
of immunity

Given that none of the vaccination approaches are universal, choice of vaccination method will be largely
determined by the type and size of the fish, protection
required, pathogen’s nature, type of immune reaction
required and the vaccine’s nature (single or multivalent), as
well as the cost which is essential for fish industry and
small fish farmers in the developing countries. New fish
vaccine development and the production of fish vaccines
require that vaccines must be effective and suitable for
large-scale production at low cost, making the vaccines
available and affordable to the aquaculture fish industry
and small fish farmers in the developing countries.
Facing economic pressure in the aquaculture industry,
intensive fish farming has increased the spread of diseases
and parasites. To manage the problem, a large amount of
antibiotics are applied in aquaculture with the hope of
enhancing production and improving the socioeconomic
profile of the fish farmers in the developing countries.
The presence of antibiotic compounds in the aquatic
environment has resulted in environmental pollution,
especially water pollution. It leads also to the development
of antibiotic-resistant bacteria making bacterial disease
control in aquaculture a challenging task. Increased mortality of Penaeus monodon larvae due to antibiotic-resistant
Vibrio harveyi infection has been reported (Karunasagar
et al. 1994). Furthermore, infectious diseases in aquaculture are caused not only by bacteria but also viruses, fungi
and parasites. Thus, vaccination is the most effective way

to protect fishes and to manage aquaculture in an environmentally friendly manner. Application of plant biotechnological tools for fish vaccine development is of
importance for aquaculture as the fish vaccines have to be
produced at a low cost and for easy scaling up, making
them accessible and affordable for not only the aquaculture
industry worldwide, but in particular for improvement of
the conditions for small fish farmers in the developing
countries.

Exploitation of plant genetic engineering
for low cost production of fish vaccines
Fish have a functional immune system similar to mammals
(innate and adaptive) and the advancement and experiences
of plant biotechnology in vaccine development for humans
and other mammals could be of importance for the development of fish vaccines. The use of plants for development
and production of recombinant vaccines offers several
advantages. Plant-based systems are more economical as
plants can be grown on a larger scale than in other systems.
Low cost is no doubt one of the most important issues in
the future development of fish vaccines. Plants also possess
the ability to carry out post-translational modifications
similar to naturally occurring systems. The plant-based
systems bypass the safety concerns inherent in live virus
vaccines.
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To date, three main plant-based techniques have been
used for the expression of a large number of vaccine
antigens, monoclonal antibodies (mAbs) and other biopharmaceuticals in plants. These are (1) stable expression
of transgenes in the nuclear genome of transgenic plants or
cell culture, (2) stable expression of transgenes in the
plastid genome of transplastomic plants by plastid genetic
engineering and (3) transient expression of transgenes in
plants. A number of reviews have covered all the three
methodologies (Streatfield 2007; Daniell et al. 2009;
Clarke and Daniell 2011; Lössl and Waheed 2011; Maliga
and Bock 2011; Yusibov et al. 2011). Each system has its
advantages and limitations and the method of choice is
largely depending on what kind of fish vaccines are to be
expressed, as briefly described in Table 2. To date, both
food and non-food crops (especially tobacco plant) have
been used for the development of a number of animal
vaccines, such as a poultry vaccine against Newcastle
disease (Hahn et al. 2007; Yang et al. 2007; Li et al. 2007;
Gómez et al.2009; Van Eck and Keen 2009; Wu et al.
2009: for reviews see Floss et al. 2007 and He et al. 2008),
rabies (Ashraf et al. 2005; Loza-Rubio et al. 2008; Roy
et al. 2010; Loza-Rubio et al. 2012), Porcine reproductive
and respiratory syndrome virus (PRRSV) and Porcine postweaning diarrhea in piglets (Chen and Liu 2011; Kolotilin
et al. 2012). The vaccine against Newcastle disease was the
first plant-made animal vaccine receiving regulatory
approval from the US Department of Agriculture (USDA)
Center for Veterinary Biologics in 2006 (www.thepoultry
site.com/poultrynews/8949/usda-issues-license-for-plant-cellproducednewcastle-disease-vaccine-for-chickens; Joensuu
et al. 2008).
Moreover, studies on plant-based animal vaccines for
protecting mink, dogs, and cats are reported (Dalsgaard
et al. 1997; Molina et al. 2004). Molina et al. (2004, 2005)
demonstrated high-level expression of a tobacco chloroplast-derived vaccine based on a B cell epitope from canine
parvovirus and the induction of neutralizing antibodies.
Three recent reviews by Floss et al. (2007), Joensuu et al.
(2008) and Rybicki (2010) have provided an overview of
production of veterinary vaccines in plants. However,
plants as expression systems for production of fish vaccines
are lagging behind compared with the plant-made veterinary vaccines for non-aquatic (land-based) animals. Based
on the special advantages of oral vaccination in aquaculture, Companjen et al. (2005) successfully expressed the
non-toxic part of the E. coli heat-labile enterotoxin LTB
fused with a viral peptide or GFP in potato tuber for oral
immunization and induction of specific humoral immune
response in carp upon feed-mediated administration. This
study demonstrated the feasibility of producing fish vaccines for oral vaccination in an edible crop and the technology shall be explored further. To boost an efficient
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delivery of plant-made oral fish vaccine to immune-competent cells in the gut mucosa, a carrier molecule i.e. LTB
in the study was fused to the oral vaccine antigens to
stimulate the uptake and immune response upon feedmediated oral immunization.. Another attempt is our own
ongoing research in production of a fish vaccine in tobacco
chloroplasts against viral nervous necrosis (VNN) caused
by Nodavirus (Clarke et al. ongoing research). VNN affects
farmed fish such as turbot, Atlantic halibut and Atlantic
cod, as well as wild fish (Grotmol et al. 1995, 1997;
Munday et al. 2002; Sommerset et al. 2005). The risk of
VNN spreading from escapes of farmed fish to wild indicates the significance of the development of a cost effective
and safe vaccine against VNN infection. The economic
importance of such a vaccine for farmed fish is self-evident. In this study, transplastomic tobacco lines expressing
RNA2 as the antigen candidate were produced and are
currently subject to various molecular analyses (Clarke
et al. unpublished results).

Engineering edible crops for the development
of fish vaccines for oral immunization
Edible crops are ideal green factories for the production of
therapeutic proteins and vaccines for oral immunization. In
aquaculture, among the current fish vaccination methods
shown in Table 1, a fish vaccine produced in an edible crop
(or microalgae) for oral immunization is undoubtedly
advantageous because oral vaccination of fish is an easy,
labour-saving and stress free method which is suitable for
all fishes independent of the fish size.
Despite the advantages and potentials of plant vaccine
production systems for animal health including aquatic
animals, there are only a few studies reporting the veterinary vaccine antigens expressed in edible crops, only one
case for fish vaccine produced in potato for oral delivery
via feed suggesting strongly that research effort is needed
to develop and advance the research field in the future for
effective management of fish health by cost effective plantmade oral fish vaccines. Successful management of fish
health will directly contribute to sustainable food fish
production in the future. To date, lettuce and potato tubers
have been used for the development of plant-based animal
vaccines (Companjen et al. 2005; Gómez et al. 2008;
Matsui et al. 2009). So far, there is no report describing
fish vaccine antigens expressed in edible crops by
plastid genome engineering, despite the technology for
plastid engineering of edible crops such as lettuce, tomato,
potato, cabbage etc. having been developed and used to
express a number of foreign proteins (Kanamoto et al.
2006; Ruf et al. 2001; Ruhlman et al. 2007, 2010; Daniell
et al. 2009; Cardi et al. 2010; Clarke and Daniell 2011;

Plant Mol Biol (2013) 83:33–40
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Table 2 Plant expression systems and their future application in fish vaccine development
Plant expression system

Fish vaccine for oral
vaccination

Fish vaccine for
injection

Fish vaccine
for immersion

Transient expression

Not feasible

Feasible and desirable

Feasible and desirable

Feasible and desirable for
both single and
multivalent vaccines

Feasible and suitable for
both single and
multivalent vaccines

Feasible and desirable for
both single and
multivalent vaccines

Advantages:
Fast and easy scaling up
Feasible for Nicotiana
benthamiana and tobacco plants
Limitations:
Not applicable in edible crops
Plastid engineering
Advantages
High level expression of foreign proteins
([70 % of total soluble proteins), suitable
for production in large quantity

An example: fish vaccine
antigen expressed in
tobacco chloroplasts
(Clarke et al. unpublished
results)

Biosafety via maternal inheritance and
inducible promoter like T7
Methods established in both food (lettuce,
soybean, tomato, potato, cabbage etc.)
and non-food crops (tobacco, poplar etc.)
Multiple genes (up to 8 genes) can be
expressed in a single event
Cost effective
Limitations
Not applicable for glycoproteins
Protein stability at room temperature
Nuclear genetic engineering
Advantages
Methods established in a
large number of food
and non-food crops
Easy and feasible
Limitations
Low expression level of recombinant proteins

Feasible but less desirable
due to the low expression
level

Feasible and suitable

Feasible but less desirable
due to the low expression
level

Report: Antigen fused with
LTB and expressed in
potato showed humoral
immune response in carp
gut (Companjen et al.
2005)

Biosafety concern as pollen contains transgene
Transgene segregation when via seed propagation

Davoodi-Semiromi et al. 2010; Kanagaraj et al. 2011;
Boyhan and Daniell 2010; Lakshmi et al. 2013). Based on
the experience from human vaccines produced in edible
crops, the development of fish vaccines in edible crops for
oral vaccination will be a reality in the future.

Regulatory constraints
It was 30 years ago when the first genetically modified (GM)
plant was produced by using Agrobacterium tumefaciens—
mediated genetic transformation (for historical perspective
see Bevan et al. 1983; Fraley et al. 1983; Herrera-Estrella
et al. 1983 and review by Vasil 2008). Thirteen years
later, the first GM crop was commercialized in 1996

(http://www.isaaa.org). Since then, there has been a fast
development with first, second and third generations of
GM plants produced worldwide. Despite the encouraging
news that the global status of commercialized biotech crops
has reached 170.3 million hectares globally in 2012
(http://www.isaaa.org), at an annual growth rate of 6 %, up
10.3 million from 160 million hectares in 2011 and with
significant benefits for farmers, the regulatory constraints
are a well-known hurdle for commercialization of biotech
crops in many countries, especially in Europe. Molecular
farming using plants or plant cell lines as a green factory to
produce vaccines and biopharmaceuticals has also made
considerable progress with commercially released plantmade therapeutic proteins, and a number of vaccines and
therapeutic proteins are undergoing clinical trials or are in
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the pipeline to be approved (Yusibov et al. 2011;
http://www.genengnews.com/gen-news-highlights/); however, it has encountered the same regulatory constraints as
other GM crops. Under the current regulatory requirements,
it’s estimated that it takes on average 7-10 million euros to
approve a GM crop for cultivation (Paul et al. 2011).
Current USDA-APHIS regulatory requirements are based
on the use of plant pathogens (Agrobacterium) for transformation or use of plant pathogenic sequences (Agrobacterium genome sequence or plant viral genome sequence,
especially the CaMV promoter). So, in order to minimize
regulatory costs, one could use the chloroplast transformation approach for molecular pharming, which doesn’t use
any plant pathogenic sequences. This approach should significantly minimize the cost of regulatory approval for field
studies. Indeed, plant-made pharmaceuticals engineered via
the chloroplast genome have been tested in the field several
years ago (Arlen et al. 2007). One among the most important
regulatory hurdles for molecular pharming is transgene
containment. Early plant-made vaccine companies were
shut down by USDA-APHIS for contamination of food/feed
grains by corn seeds expressing human therapeutic proteins
(e.g. Prodigene). Such regulatory challenges could therefore
be avoided by not expressing vaccines in seeds. For example, expressing vaccine antigens in leaves facilitates their
harvest before appearance of any reproductive structures,
thereby avoiding contamination via pollen or seeds (Daniell
et al. 2009). In addition, expressing vaccine antigens via the
chloroplast genome facilitates maternal inheritance of
transgenes and minimizes or eliminates out-cross via pollen
(Daniell 2007; Daniell et al. 1998).
Another important cost in regulatory approval is the need
for release into the environment, requiring large acreage of
field studies in different geographical locations. However,
for molecular pharming using the chloroplast transformation
approach, high levels of expression result in minimal acreage. For example, one acre of cultivation could produce up
to 360 million doses of vaccines (Koya et al. 2005; Watson
et al. 2004). Thus, the production could be contained within
the greenhouse, eliminating the need for field release.
So far, none of the plant-made vaccines has been
approved for oral delivery, an essential requirement for low
cost fish vaccine. Bioencapsulation protects vaccine antigens expressed within plant cells, and they are released in
the gut by the action of microbes colonizing the gut (Limaye et al. 2006; Kwon et al. 2013a, b; Arlen et al. 2008;
Davoodi-Semiromi et al. 2010). However, neither the
transient viral expression system that infects plant cells nor
low level expression of stable nuclear expression is ideal
for oral delivery of vaccines. However, several oral vaccines expressed via the chloroplast genome have been
shown to be effective against pathogen or toxin challenge
(Davoodi-Semiromi et al. 2010; Arlen et al. 2008) or
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immune disorders (Ruhlman et al. 2007; Verma et al.
2010). In addition, regulatory agencies require demonstration of long-term stability of vaccine at room temperature. Such stability has been shown by storage of
lyophilized leaf materials for several months or years
expressing human therapeutic proteins (Kwon et al. 2013a,
b), vaccine antigens or autoantigens (Lakshmi et al. 2013,
Kwon et al. 2013a, b). Moreover, the process of lyophilization eliminates microbes that colonize plants, an important regulatory requirement (Kwon et al. 2013a). In
addition, the concentration of vaccine antigens is increased
15–25 fold, significantly reducing the amount of plant
materials required for effective vaccination (Kwon et al.
2013a). The aforementioned advantages make the lettuce
chloroplast system ideal for oral vaccines and several
human therapeutic proteins have been expressed at high
levels in lettuce chloroplasts (Davoodi-Semiromi et al.
2010; Kanagaraj et al., 2011; Boyhan and Daniell 2010;
Lakshmi et al. 2013; Ruhlman et al. 2007, 2010). Future
studies should therefore focus on edible leaves rather than
tobacco that has nicotine and other alkaloids, not permitted
by any of the global regulatory agencies.

Conclusions
With the challenges of the growing world population, food
security demand and unpredictable climate change, aquatic
fish health and management have become a global concern
which affects protein-based food security, the environment,
and the aquaculture industry and millions of fish farmers in
the developing countries. To use biotechnological tools to
manipulate plants for low-cost and safe vaccine production
for farmed fish is a research field which needs to be
advanced and strengthened. This review has addressed
these issues and provided an overview of the current situation in fish health management, the status of fish vaccine
and vaccinations, as well as how to explore plant genetic
engineering for the development and cost-effective production of fish vaccines. The utilization of plants for lowcost and large quantity production of fish vaccines with
oral immunization by plant genetic engineering, especially
plastid genetic engineering of edible crops, should be
emphasized. Oral vaccination is of special importance for
fishes weighing less than 20 g. To promote an efficient
delivery of plant-made oral fish vaccine to immune-competent cells in the gut mucosa, a carrier molecule such as
LTB or CTB should be fused to the oral vaccine antigens to
stimulate the uptake and immune response upon feedmediated oral immunization. Altogether, there is an urgent
need for the research community to advance and implement plant genetic engineering of edible crops for production of fish vaccines for oral vaccination via feed.
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Acknowledgments We thank the Research Council of Norway for
grant GLOBVAC NFR 192510, Bioforsk for providing core funding
for ‘‘Plants for non-food application’’ to Dr Jihong Liu Clarke as well
as the Bioforsk SIS program to Dr Inger Martinussen and the NIH R01
HL 109442 and NIH R01 HL 107904, Bill and Melinda Gates
Foundation Global Health Grant OPP 1031406 and the Juvenile
Diabetes Research Foundation Grant 17-2011-286 to Dr. Henry Daniell. The authors thank Nicholas Clarke for his critical reading.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.

References
Arlen PA, Falconer R, Cherukumilli S, Cole A, Cole AM, Oishi KK,
Daniell H (2007) Field production and functional evaluation of
chloroplast-derived interferon alpha 2b. Plant Biotechnol J
5:511–525
Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi
A, Daniell H (2008) Effective plague vaccination via oral
delivery of plant cells expressing F1-V antigens in chloroplasts.
Infect Immun 76:3640–3650
Ashraf S, Singh PK, Yadav DK, Shahnawaz M, Mishra S, Sawant SV,
Tuli R (2005) High level expression of surface glycoprotein of
rabies virus in tobacco leaves and its immunoprotective activity
in mice. J Biotechnol 119:1–14
Bevan MW, Flavell RB, Chilton MD (1983) A chimeric antibioticresistance gene as a selectable marker for plant-cell transformation. Nature 304:184–187. doi:10.1038/304184a0
Boyhan D, Daniell H (2010) Low cost production of proinsulin in
tobacco and lettuce chloroplasts for injectable or oral delivery of
functional insulin and c-peptide. Plant Biotechnol J 9:585–598
Cardi T, Lenzi P, Maliga P (2010) Chloroplasts as expression
platforms for plant-produced vaccines. Expert Rev Vaccines
9:893–911
Chen X, Liu J (2011) Generation and immunogenicity of transgenic
potato expressing the GP5 protein of porcine reproductive and
respiratory syndrome virus. J Virol Methods 173(1):153–158.
doi:10.1016/j.jviromet.2011.02.001
Clarke JL, Daniell H (2011) Plastid biotechnology for crop production: present status and future perspectives. Plant Mol Biol
76:211–220
Companjen AR, Florack DE, Bastiaans JH, Matos CI, Bosch D,
Rombout JH (2005) Development of a cost-effective oral
vaccination method against viral disease in fish. Dev Biol
(Basel) 121:143–150
Dalsgaard K, Uttenthal A, Jones TD, Xu F, Merryweather A,
Hamilton WD, Langeveld JP, Boshuizen RS, Kamstrup S,
Lomonossoff GP, Porta C, Vela C, Casal JI, Meloen RH,
Rodgers PB (1997) Plant derived vaccine protects target animals
against a viral disease. Nat Biotechnol 15:248–252
Daniell H (2007) Transgene containment via maternal inheritance.
Proc Natl Acad Sci USA 104:6879–6881
Daniell H, Datta R, Varma S, Gray S, Lee SB (1998) Containment of
herbicide resistance through genetic engineering of the chloroplast genome. Nat Biotech 16:345–348
Daniell H, Singh ND, Mason H, Streatfield SJ (2009) Plant-made
vaccine antigens and biopharmaceuticals. Trends Plant Sci
14:669–679
Davoodi-Semiromi A, Schreiber M, Samson N, Verma D, Singh ND,
Chakrabarti D, Daniell H (2010) Chloroplast-derived vaccine

39
antigens confer dual immunity against cholera and malaria by
oral or injectable delivery. Plant Biotechnol J 8:223–242
Ellis LJ (2009) Fishing murky waters: China’s aquaculture challenges—upstream and downstream. Business forum China pp 1–2
Evelyn TPT (1997) A historical review of fish vaccinology. In: Gudding
R, Lillehaug A, Midtlyng PJ, Brown F (eds) Developments in
biological standardization: fish vaccinology, vol 90. International
Association of Biological Standardization, Basel, pp 3–12
FAO (2010) The state of world fisheries and aquaculture. Rome, FAO
FAO (2012) The state of world fisheries and aquaculture. Rome,
FAO. http://www.fao.org/docrep/016/i2727e/i2727e.pdf
Floss DM, Falkenburg D, Conrad U (2007) Production of vaccines
and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Trans Res 16:315–332
Fraley RT, Rogers SG, Horsch RB, Sanders PR, Flick JS, Adams SP,
Bittner ML, Brand LA, Fink CL, Fry JS, Galluppi GR, Goldberg
SB, Hoffmann NL, Woo SC (1983) Expression of bacterial
genes in plant cells. Proc Natl Acad Sci USA 80:4803–4807
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Gómez E, Chimeno Zoth S, Vázquez A, Rovere C, Berinstein A
(2009) Expression of hemagglutinin—neuraminidase glycoprotein of newcastle disease virus in agroinfiltrated Nicotiana
benthamiana plants. J Biotechnol 144:337–340
Grotmol S, Totland GK, Kvellestad A, Fjell K, Olsen AB (1995)
Mass mortality of larval and juvenile hatchery-reared halibut
(Hippoglossus hippoglossus L.) associated with the presence of
virus-like particles in vacuolated lesions of the central nervous
system and retina. Bull Eur Fish Pathol 15:176–180
Grotmol S, Totland GK, Thorud K, Hjeltnes BK (1997) Vacuolating
encephalopathy and retinopathy associated with a nodavirus-like
agent: a probable cause of mass mortality of cultured larval. Dis
Aquat Org 29(8):5–97
Hahn BS, Jeon IS, Jung YJ, Kim JB, Parl JS, Ha SH, Kim KH, Kim
HM, Yang JS, Kim YH (2007) Expression of hemagglutininneuraminidase protein of Newcastle disease virus in transgenic
tobacco. Plant Biotechnol Rep 1:85–92
He Z, Du X, Yao W, Dai J (2008) Pharmaceutical proteins produced
in plant bioreactor in recent years. Afr J Biotechnol 7:4917–4925
Herrera-Estrella L, De Block M, Messens E, Hernalsteens J-P, Van
Montagu M, Schell J (1983) Chimeric genes as dominant
selectable markers in plant-cells. EMBO J 2:987–995
Joensuu JJ, Niklander-Teeri V, Brandle JE (2008) Transgenic plants
for animal health: plant-made vaccine antigens for animal
infectious disease control. Phytochem Rev 7:553–577
Kanagaraj AP, Verma D, Daniell H (2011) Expression of dengue-3
premembrane and envelope polyprotein in lettuce chloroplasts.
Plant Mol Biol 76:323–333
Kanamoto H, Yamashita A, Asao H, Okumura S, Takase H, Hattori
M, Yokota A, Tomizawa K (2006) Efficient and stable
transformation of Lactuca sativa L. cv. Cisco (lettuce) plastids.
Transgenic Res 15:205–217
Karunasagar Pai R, Malathi GR, Karunasagar I (1994) Mass mortality
of Penaeus monodon larvae due to antibiotic-resistant Vibrio
harveyi infection. Aquaculture 128:203–209
Kolotilin I, Kaldis A, Devriendt B, Joensuu J, Cox E, Menassa R
(2012) Production of a subunit vaccine candidate against porcine
post-weaning diarrhea in high-biomass transplastomic tobacco.
PloS One 7 doi:10.1371/journal.pone.0042405
Koya V, Moayeri M, Leppla SH, Daniell H (2005) Plant based
vaccine: mice immunized with chloroplast- derived anthrax
protective antigen survive anthrax lethal toxin challenge. Infect
Immun 73:8266–8274
Kwon KC, Nityanandam R, New JS, Daniell H (2013a) Oral delivery
of bioencapsulated exendin-4 expressed in chloroplasts lowers

123

40
blood glucose level in mice and stimulates insulin secretion in
beta-TC6 cells. Plant Biotechnol J 11:77–86
Kwon KC, Verma D, Singh NK, Herzog RW, Daniell H (2013b) Oral
delivery of human biopharmaceuticals, autoantigens and vaccine
antigens bioencapsulated in plant cells. Adv Drug Deliv Rev.
doi:10.1016/j.addr.2012.10.005
Lakshmi PS, Verma D, Yang X, Lloyd B, Daniell H (2013) Low cost
tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation
in vitro. PLoS ONE 8:e54708
Li J, Chen M, Liu XW et al (2007) Transient expression of an active
human interferon-beta in lettuce. Sci Hortic 112(3):258–265
Limaye V, Koya M, Samsam N, Daniell H (2006) Receptor mediated
oral delivery of a bioencapsulated green fluorescent protein
expressed in transgenic chloroplasts into the mouse circulatory
system. FASEB J 20:959–961
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